Jon Hollick

Managing Director & Head of Research Breakpoint Therapeutics

Wednesday 28th January 2026

Targeting Polθ’s Dual Domains to Guide Candidate Selection & Strategic Partnering

11:00 am

• See how Breakpoint Therapeutics is guiding candidate selection by comparing helicase vs. polymerase inhibition to inform domain targeting

• Presenting Breakpoint’s candidate molecule and second-generation compound with updated preclinical efficacy and safety data

• Contextualizing Breakpoint’s program within the broader Polθ landscape to highlight differentiation and partnering potential

Thursday 29th January 2026

Panel: Uniting Founders and Funders to Align Scientific Vision with Investment Strategy

9:30 am

• Bringing together academic founders and investors to explore what makes DDR programs fundable

• Examining licensing, MTA bottlenecks, and funding models across early and late-stage ventures

• Offering insights into risk assessment, strategic partnerships, and scaling innovation